MannKind Corporation (MNKD)
Chart Events
Performance Outlook
| Previous Close | 3.0600 |
| Open | 3.0600 |
| Bid | 2.9700 x 47300 |
| Ask | 2.9600 x 3200 |
| Day's Range | 2.9200 - 3.0850 |
| 52 Week Range | 0.8000 - 3.2000 |
| Volume | 3,687,113 |
| Avg. Volume | 2,583,753 |
| Market Cap | 686.173M |
| Beta (5Y Monthly) | 2.10 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2090 |
| Earnings Date | Nov 04, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.10 |
Fair Value
Related Research
- Benzinga
The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 19) * Aligos Therapeutics Inc (NASDAQ: ALGS) * ALX Oncology Holdings Inc (NASDAQ: ALXO) * Atara Biotherapeutics Inc (NASDAQ: ATRA) * China Biologic Products Holdings Inc (NASDAQ: CBPO) (announced a go-private transaction) * Corcept Therapeutics Incorporated (NASDAQ: CORT) (announced a ruling upholding the validity of all claims of U.S. Patent No. 10,195,214) * Idera Pharmaceuticals Inc (NASDAQ: IDRA) * Infinity Pharmaceuticals Inc. (NASDAQ: INFI) * Pacira Biosciences Inc (NASDAQ: PCRX) * Prelude Therapeutics Inc (NASDAQ: PRL) * Replimune Group Inc (NASDAQ: REPL) * Rocket Pharmaceuticals Inc (NASDAQ: RCKT) * Spruce Biosciences Inc (NASDAQ: SPRB) * TRACON Pharmaceuticals Inc (NASDAQ: TCON) * Travere Therapeutics, Inc. (RTRX) * Trillium Therapeutics Inc (NASDAQ: TRIL) * Twist Bioscience Corp (NASDAQ: TWST) * Urovant Sciences Ltd (NASDAQ: UROV) * Veracyte Inc (NASDAQ: VCYT)Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov. 19) * Benitec Biopharma Inc (NASDAQ: BNTC) * Kiromic Biopharma Inc (NASDAQ: KRBP) * Polypid Ltd (NASDAQ: PYPD)Stocks In Focus Amarin's Late-Stage Vascepa Trial In China Meets Study Goals Amarin Corporation plc (NASDAQ: AMRN) announced positive, statistically significant top-line results from a Phase 3 clinical trial of its fish oil pill Vascepa conducted in China by its partner, Edding. The study, which investigated Vascepa as a treatment for patients with very high triglycerides, met its primary efficacy endpoint as defined in the clinical trial protocol and demonstrated a safety profile similar to placebo, the company said.The company said the findings are being prepared to support Edding's dossier for seeking regulatory approval of Vascepa in mainland China.Amarin shares were jumping 18.06% to $5.36 premarket Friday.Mesoblast Strikes Stem Cell Therapy Collaboration Agreement With Novartis Mesoblast limited (NASDAQ: MESO) announced an exclusive worldwide license and collaboration agreement with Novartis AG (NYSE: NVSP) for the development of its mesenchymal stromal cell product remestemcel-L, with an initial focus on the development of the treatment of acute respiratory distress syndrome, including that associated with COVID-19.The agreement provides for Novartis making a $50-million upfront payment, including $25 million in equity. Mesoblast may also receive a total of $505 million pending achievement of precommercialization milestones for ARDS indications. It could also receive additional payments post-commercialization of up to $750 million based on achieving certain sales milestones and tiered double-digit royalties on product sales.Separately, Mesoblast reported first-quarter revenue of $1.3 million, down from $17 million in the year-ago quarter, which included $15 million in upfront milestone payment received for the strategic partnership with Grunenthal GmbH.The net loss per share widened from 1.10 cents to 4.21 cents.The stock jumped 17.73% premarket to $13.88. Lilly's Drug Combo Issued Emergency Use Authorization For COVID-19 Eli Lilly And Co (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) said the FDA issued an emergency use authorization for the distribution and emergency use of baricitinib to be used in combination with Gilead Sciences, Inc.'s (NASDAQ: GILD) remdesivir in hospitalized adult and pediatric patients two years of age or older with suspected or laboratory confirmed COVID-19 who require supplemental oxygen, invasive mechanical ventilation or extracorporeal membrane oxygenation.Baricitinib, discovered by Incyte, has been licensed to Lilly.Separately, Lilly announced a R&D and exclusive license agreement to utilize Precision BioSciences Inc's (NASDAQ: DTIL) proprietary ARCUS genome editing platform for the R&D of potential in vivo therapies for genetic disorders, with an initial focus on Duchenne muscular dystrophy and two other undisclosed gene targets.Lilly shares were up 0.7% premarket at $144.41, while Gilead shares were down 1.62% at $59.65.Precision BioSciences shares were jumping 28.1% to $12.40 in premarket trading Friday.Pfizer, BioNTech To Submit EUA For Coronavirus Vaccine Friday Pfizer Inc. (NYSE: PFE) and BioNTech SE - ADR (NASDAQ: BNTX) confirmed that they would submit emergency use application for their coronavirus vaccine candidate to the FDA on Friday.In premarket trading Friday, Pfizer was adding 1.6% to $36.77 and BioNTech shares were rallying 6.99% to $101.57.Related Link: The Week Ahead In Biotech: The Vaccine Updates, Drug Presentations, And FDA Decisions That Will Move The MarketsBeiGene's In-Licensed Osteoporosis Drug Gets Label Expansion In China Beigene Ltd (NASDAQ: BGNE) said the China National Medical Products Administration has approved Xgeva for the prevention of skeletal-related events in patients with bone metastases from solid tumors and in patients with multiple myeloma.Developed by Amgen, Inc. (NASDAQ: AMGN) and licensed to BeiGene in China under a strategic collaboration commenced earlier this year, Xgeva is also approved and marketed in China for the treatment of adults and skeletally mature adolescents with giant cell tumor of the bone that is unresectable or where surgical resection is likely to result in severe morbidity.MannKind Gets Final Development Milestone Payment Of $12.5M For Hypertension Drug MannKind Corporation (NASDAQ: MNKD) said it has achieved the final development milestone under its licensing and collaboration agreement with United Therapeutics Corporation (NASDAQ: UTHR) for the development and commercialization of a dry powder formulation of treprostinil. The fourth milestone payment fetched MannKind $12.5 million.View more earnings on IBBTreprostinil Technosphere is an investigational product currently being evaluated in clinical trials for the treatment of pulmonary arterial hypertension."We are looking forward to working with United Therapeutics during the first part of 2021 to prepare an FDA submission for TreT," said MannKind CEO Michael Castagna.In after-hours trading, MannKind shares were up 2.54% to $2.83.AstraZeneca's Imfinzi Approved For Additional Dosage In Lung, Bladder Cancers AstraZeneca plc (NASDAQ: AZN) said its Imfinzi has been approved in the U.S. for an additional dosing option, a 1,500mg fixed dose every four weeks in the approved indications of unresectable Stage 3 non-small cell lung cancer after chemoradiation therapy and previously treated advanced bladder cancer.In premarket trading Friday, the shares were up 2.07% to $55.15.Aptevo Confirms Takeover Interest For $50/Share In Cash Aptevo Therapeutics Inc (NASDAQ: APVO) confirmed it has received an unsolicited non-binding indication of interest from Tang Capital Partners, LP expressing its interest in acquiring all of the outstanding shares of Aptevo that it does not already own for $50 per share in cash.While recommending that shareholders take no action at this juncture, the company said its board will carefully evaluate and consider this indication of interest in due course in the context of Aptevo's strategic plans, and its ongoing review of a broad range of opportunities to enhance stockholder value.After jumping 29.10% to $45.69 in regular trading on the speculation, the stock was down slightly premarket at $45.65.Affimed Reports Positive Phase 1 Results For Cancer Drug Combo Affimed NV (NASDAQ: AFMD) announced the publication in Blood of positive results for the Phase 1b study of AFM13, a CD30/CD16A innate cell engager, in combination with Merck & Co., Inc.'s (NYSE: MRK) Keytruda.The results demonstrate promising signs of efficacy including an objective response rate of 88% at the highest treatment dose, as well as a complete response of 46% in patients with relapsed/refractory Hodgkin lymphoma. As a monotherapy, Keytruda demonstrated an ORR of 69% and a CR of 22.4% in the KEYNOTE-087 trial.Affimed shares were up 1.66% to $4.90 in after-hours trading.Offerings Avrobio Inc (NASDAQ: AVRO) said it has priced its underwritten public offering of 5 million shares of its common stock at $15 per share for raising gross proceeds of $75 million. The offering is expected to close on or about Nov. 24, subject to customary closing conditions.The stock fell 7.13% to $15.77 in after-hours trading.On The Radar PDUFA Dates Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) has a binary event with respect to its NDA for Lonfarnib in progeria and progeroid laminopathies.Clinical Readout/Presentations 2020 Society for Neuro-Oncology Meeting Presentations: Kazia Therapeutics Ltd (NASDAQ: KZIA): Phase 2 data for GDC-0084 in glioblastoma multiformeConnective Tissue Oncology Society Virtual Annual Meeting Presentations Karyopharm Therapeutics Inc (NASDAQ: KPTI): data from the Phase 3 portion of the SEAL study of Xpovio in advanced dedifferentiated liposarcomaCogent Biosciences Inc (NASDAQ: COGT): final clinical data from its Phase 1/2 study of PLX9486 in gastrointestinal stromal tumorsEarnings Burning Rock Biotech Ltd (NASDAQ: BNR) (before the market open)IPOs San Diego, California-based Maravai Lifsciences Holding, Inc. priced its upsized initial public offering of 60 million shares at $27 each, compared to the estimated price range of $24-$27.The shares of the company -- which provides critical products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases -- will be listed on the Nasdaq under the ticker symbol "MRVI."Sotera Health Company, a global provider of sterilization and lab testing and advisory services to the medical device and pharmaceutical industries, priced its 46.6-million share IPO at $23, the upper end of the estimated price range of $20-$23. The shares of the Broadview Heights, Ohio-based company will be listed on the Nasdaq under the ticker symbol "SHC."Related Link: Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates See more from Benzinga * Click here for options trades from Benzinga * The Daily Biotech Pulse: Aquestive's Positive FDA Meeting, Prevail Awarded Patent, Neuro-Oncology Conference Gets Underway * The Daily Biotech Pulse: Kazia Jumps On Data Readout, Clinical Hold On Cellectis' Blood Cancer Study Lifted(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- GlobeNewswire
MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics
WESTLAKE VILLAGE, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that it has achieved the final development milestone under its licensing and collaboration agreement with United Therapeutics for the development and commercialization of a dry powder formulation of treprostinil. Treprostinil Technosphere (“TreT”) is an investigational product currently being evaluated in clinical trials for the treatment of pulmonary arterial hypertension (PAH). All current clinical trials are now fully enrolled, including the BREEZE study in patients with PAH and a pivotal pharmacokinetics study in healthy subjects, both of which are being conducted by United Therapeutics, as well as a human factors study being conducted by MannKind. In addition, MannKind’s stability program for TreT has reached the milestone required for a regulatory filing.“We are looking forward to working with United Therapeutics during the first part of 2021 to prepare an FDA submission for TreT,” said Michael Castagna, Chief Executive Officer of MannKind.MannKind has now received all of the milestone payments that were specified in its agreement with United Therapeutics. MannKind remains entitled to receive low double-digit royalties on net sales of TreT. MannKind will also manufacture supplies of TreT for United Therapeutics and will earn a manufacturing margin.About MannKind Corporation MannKind Corporation (NASDAQ: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.Forward-Looking Statements This press release contains forward-looking statements that involve risks and uncertainties. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties detailed in MannKind's filings with the SEC. For a discussion of these and other factors, please refer to MannKind’s annual report on Form 10-K for the year ended December 31, 2019 as well as MannKind’s other filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.Company Contact: 818-661-5000 ir@mannkindcorp.com
- PR Newswire
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating MannKind Corporation for Potential Breaches of Fiduciary Duty By Its Board of Directors
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of MannKind Corporation (NASDAQ: MNKD).
